(TheNewswire)
London, Ontario - TheNewswire - December 3 , 2020- Interest in Sernova Corp. (TSXV:SVA) (OTC:SEOVF) (FSE:PSH) isgrowing rapidly.
With its medical advances and latest announcements, Sernova hasgarnered attention in the fields of regenerative medicine, diabetes,and more recently, from the media.
News from its current clinical trials at the University of Chicagorecently caught the eyes of CTV Medical Reporter Celine Zadorski, whohas details :
Click URL to ViewVideo: https://london.ctvnews.ca/video?clipId=2081991&jwsource=cl
How Sernova's Pouc h W orks:
Sernova's innovative Cell Pouch TM therapeutic device - a potential cure for Type 1 Diabetes(T1D) - is a device smaller than a business card that is placed deepbelow a patient's skin. This in turn creates vascularized tissuechambers which then hold therapeutic cells. In just a short time, thePouch eliminates the need for finger pricks and insulin pumps.
Sernova aims to be the company to introduce a cure for T1D and willlikely see more media coverage in the months to come – andnot just from medical journals. The nearly 40 million people inNorth America living with Diabetes are certainly receptive to learn ofadvancements in the field.
Clinical trials ongoing at the University of Chicago have implantedfive Type 1 Diabetes patients with Sernova's Cell Pouch. The CellPouch with implanted cells has, in fact, been shown to release insulinand it is being measured by c-peptide, an indicator of insulin,present in patients' blood. Further, it has shown a reduction in lifethreatening hypoglycaemia events or episodes that diabetes patientsexperience, according to Delfina Siroen, Senior Director of Researchat Sernova. Initial findings are promising.
Sernova researchers and team members are busy developing furthermedical innovations which will soon help people living with chronicdiseases like haemophilia A, thyroid disease and T1D.
Sernova has been invited to share recent developments at the American Society of Transplant Surgeons 21 st Annual State of the Art Winter Symposium .
Dr. Piotr Witkowski, principal investigator in Sernova's ongoing PhaseI/II clinical trial on the safety and efficacy of Sernova's Cell Pouchfor transplantation, will present to more than 600 transplantprofessionals as part of the Oral Abstract Session II on January 15,2021.
F or further details and media inquiries, pleasecontact:
Mr. Dominic Gray
Sernova Corp
Tel: (519) 858-5126
dominic.gray@sernova.com
Forward-Looking Information
This release may contain forward-looking statements. Forward-lookingstatements are statements that are not historical facts and aregenerally, but not always, identified by the words “expects”,“plans”, “anticipates”, “believes”, “intends”,“estimates”, “projects”, “potential” and similarexpressions, or that events or conditions “will”, “would”,“may”, “could” or “should” occur. Although TheNewswirebelieves the expectations expressed in such forward-looking statementsare based on reasonable assumptions, such statements are notguarantees of future performance and actual results may differmaterially from those in forward-looking statements. Forward-lookingstatements, are based on the beliefs, estimates and opinions on thedate such statements were made. TheNewswire expressly disclaims anyintention or obligation to update or revise any forward-lookingstatements whether as a result of new information, future events orotherwise.
Copyright (c) 2020 TheNewswire - All rights reserved.